de Boer Daniel Anton 4
4 · ProQR Therapeutics N.V. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
ProQR (PRQR) CEO Daniel de Boer Buys 150,000 Shares
What Happened
Daniel Anton de Boer, CEO of ProQR Therapeutics N.V. (PRQR), acquired 150,000 shares in an open-market purchase on July 7, 2026, at $1.59 per share, for a total cost of $238,500. This was a direct purchase (transaction code P), which is a straightforward insider buy rather than a sale or option exercise.
Key Details
- Transaction date: 2026-07-07; reported on Form 4 filed 2026-07-08 (timely filing).
- Transaction type: Open-market purchase (Code P).
- Shares acquired: 150,000 at $1.59 per share.
- Total value: $238,500.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes/plans: None disclosed in the provided excerpt (no 10b5-1 plan or tax withholding noted).
Context
Insider purchases are often viewed as a positive signal because executives are buying company stock with personal funds, but they are only one data point and do not guarantee future performance. This filing reports a straightforward buy (not an option exercise, gift, or award).
Insider Transaction Report
Form 4
de Boer Daniel Anton
DirectorChief Executive Officer
Transactions
- Purchase
Ordinary Shares
2026-07-07$1.59/sh+150,000$238,500→ 150,000 total
Signature
/s/ Pieter Erik de Ridders, Attorney-in-Fact|2026-07-08